Evidence map›Paper›PMID 26515679›Full record

ReviewLancet (London, England)2015

Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection.

Molebogeng X Rangaka, Solange C Cavalcante, Ben J Marais, Sok Thim, Neil A Martinson, Soumya Swaminathan, Richard E Chaisson

Erratum issued Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Lancet (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03302299 (URBAN ARCH), which is not on this map. Cited by 97 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 7 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03302299 phase4completednot on this mapstarted 2017, after this paper: background citation

URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence

TypeinterventionalSponsorUniversity of California, San FranciscoRan2017 to 2021Enrolled302ConditionsTuberculosis, HIV/AIDS, Alcohol AbuseArmsIsoniazid 300 Mg ORAL TABLET, Pyridoxine 25 Mg Oral Tablet
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 7 syntheses or guidelines pooled it, 217 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

7 authors at 6 institutions in 6 countries.

Molebogeng X RangakaInstitute of Epidemiology and Health, University College London, London, UK; Department of Medicine, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Solange C CavalcanteEvandro Chagas National Institute of Infectious Diseases, Rio de Janeiro, Brazil.
Ben J MaraisChildren's Hospital at Westmead and the Centre for Research Excellence in Tuberculosis, University of Sydney, Australia.
Sok ThimCambodian Health Committee, Phnom Penh, Cambodia.
Neil A MartinsonPerinatal HIV Research Unit, University of Witwatersrand, Soweto, South Africa.
Soumya SwaminathanNational Institute for Research on Tuberculosis, Chennai, India.
Richard E ChaissonCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: rchaiss@jhmi.edu.
Cambodian Institute for Cooperation and Peace · KHInstituto Evandro Chagas · BRNational Institute of Research in Tuberculosis · INPerinatal HIV Research Unit · ZAUniversity of Cape Town · ZAUniversity of Sydney · AU

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Impact of TB on Outcome of HIV in Pregnant WomenR01HD064354 · NICHD · JOHNS HOPKINS UNIVERSITY · PI CHAISSON, RICHARD E. · 2010 to 2014
$3.0M
A Smoking Cessation Trial in HIV-infected patients in South AfricaR01DA030276 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GOLUB, JONATHAN E. · 2011 to 2014
$2.0M
Medical Research CouncilNIAID NIH HHS P30 AI094189NIAID NIH HHS P30-AI-094189NICHD NIH HHS R01 HD064354NICHD NIH HHS R01 HD064354-03NIDA NIH HHS R01 DA030276NIDA NIH HHS R01 DA030276-01A1PHS HHS 2000-2009-32589
6 · The paper itself

Abstract

The billions of people with latent tuberculosis infection serve as the seedbeds for future cases of active tuberculosis. Virtually all episodes of tuberculosis disease are preceded by a period of asymptomatic Mycobacterium tuberculosis infection; therefore, identifying infected individuals most likely to progress to disease and treating such subclinical infections to prevent future disease provides a crucial opportunity to interrupt tuberculosis transmission and reduce the global burden of tuberculosis disease. Programmes focusing on single strategies rather than comprehensive programmes that deliver an integrated arsenal for tuberculosis control might continue to struggle. Tuberculosis preventive therapy is a poorly used method that is essential for controlling the reservoirs of disease that drive the epidemic. Comprehensive control strategies that combine preventive therapy for the most high-risk populations and communities with improved case-finding and treatment, control of transmission, and health systems strengthening could ultimately lead to worldwide tuberculosis elimination. In this Series paper we outline challenges to implementation of preventive therapy and provide pragmatic suggestions for overcoming them. We further advocate for tuberculosis preventive therapy as the core of a renewed worldwide focus to implement a comprehensive epidemic control strategy that would reduce new tuberculosis cases to elimination targets. This strategy would be underpinned by accelerated research to further understand the biology of subclinical tuberculosis infections, develop novel diagnostics and drug regimens specifically for subclinical tuberculosis infection, strengthen health systems and community engagement, and enhance sustainable large scale implementation of preventive therapy programmes.

Indexed as

AIDS-Related Opportunistic InfectionsAntitubercular AgentsEarly DiagnosisHealth PolicyHealth PromotionHumansLatent TuberculosisTuberculosisAntitubercular Agents

Identifiers

PMID26515679
PMCPMC4684745
OpenAlexW1884297107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.